-
Specialty Pharmaceutical Landscape: Q&A with Irina Koffler
Irina Koffler joined Mizuho as Managing Director and senior specialty pharmaceutical research analyst in 2015
-
Ties that Bind: How HCA's Big Data Transforms Care
A data set by itself, even if as extensive as HCA's, is useless unless knowledge from analysis of that data is tightly bound to process change. We learned that, and a lot more, at the MSUSA Big Data Day at HCA at the company yesterday.
-
UC Irvine 2016 Insights: Watch the Regulation, Not the Legislation
If we had to pick one conference to attend each year, the UCI HC Forecast Conference would be it
-
An Examination of Hospital Valuation Methods
Valuation is perhaps the most difficult and delicate art practiced by analysts and investors
-
Historical Healthcare Performance, Election Years and 2016 Top Picks
Most investors would agree that elections matter to the performance of healthcare services stocks
-
2016 Biotech Preview: TSRO Our Top Pick; Pricing, Immuno-Onc Trends to Continue
Our top biotech pick for 2016 is TSRO. We like VARUBI's chances of success and think two data readouts in 1H16 for the PARP inhibitor niraparib could be even larger catalysts for the stock